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Novelty and Impact: While many pregnancy-related factors are associated with 
reduced endometrial cancer risk, it remains unclear whether pregnancy-related 
complications (e.g., hypertensive conditions) are associated with risk. In the present 
study, the reduced endometrial cancer risk associated with higher number of births and 
later age at birth suggests the important role of hormonal and/or cell clearance 
mechanisms in endometrial carcinogenesis. Whereas, increased risks associated with 














pre-existing and gestational hypertension, as well as preeclampsia suggest that 
immunologic and/or inflammatory etiologies also may be relevant. 
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Many pregnancy-related factors are associated with reduced endometrial cancer risk. 
However, it remains unclear whether pregnancy-related complications (e.g., 
hypertensive conditions) are associated with risk and whether these associations vary 
by endometrial cancer subtype. Thus, we evaluated the risk of endometrial cancer, 
overall and by subtype, in relation to pregnancy-related factors, pregnancy 
complications, and birth characteristics. Utilizing population-based register data from 
four Nordic countries we conducted a nested case-control analysis of endometrial 
cancer risk. We included 10,924 endometrial cancer cases and up to 10 matched 
controls per case. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived 
from unconditional logistic regression models. We further evaluated associations by 
individual histology (i.e., endometrioid, serous, etc.) or, for rare exposures (e.g., 
pregnancy complications), by dualistic Type (Type I (n=10,343) and Type II (n=581)).  
Pre-existing and pregnancy-related hypertensive conditions were associated with 
increased endometrial cancer risk [OR (95% CI): pre-existing hypertension 1.88 (1.39-
2.55); gestational hypertension 1.47 (1.33-1.63); preeclampsia 1.43 (1.30-1.58)], with 
consistent associations across dualistic Type. Increasing number of pregnancies [≥four 
versus one birth: 0.64 (0.59-0.69)] and shorter time since last birth [<10 versus ≥30 
years: 0.34 (0.29-0.40)] were associated with reduced endometrial cancer risk, with 
consistent associations across most subtypes. Our findings support the role for both 
hormonal exposures and cell clearance as well as immunologic/inflammatory etiologies 
for endometrial cancer. This research supports studying endometrial hyperplasia, a 
precursor condition of endometrial cancer, in the context of pregnancy-related 














exposures, as this may provide insight into the mechanisms by which pregnancy affects 


























The risk of endometrial cancer is dependent on events related to hormonal exposures 
during a woman’s life. Thus, various aspects of reproduction and use of exogenous 
hormones have been extensively explored.1 Pregnancy is known to confer long-term 
protection against endometrial cancer.1 Conversely, nulliparity is associated with an 
elevated endometrial cancer risk.1 The hormonal milieu of pregnancy is characterised 
by elevated levels of estrogen, progesterone, and intrauterine growth factors, almost 
exclusively produced by the placenta.2 The pregnancy history of women with 
endometrial cancer has been examined with regard to timing of births3-7, twin births, and 
sex of offspring.8 Recent data indicate that the associations between established 
endometrial cancer risk factors: high BMI and diabetes, and some reproductive factors 
(e.g., parity) were stronger for Type I tumors compared with Type II tumors, while 
associations between other reproductive factors (e.g., age at menarche) may be slightly 
stronger for Type II tumors, albeit based on limited data.9, 10 Few studies have evaluated 
associations of pregnancy and birth-related characteristics with endometrial cancer by 
dualistic Type (I and II) or histologic subtype. Pregnancy complications such as 
preeclampsia also have been examined in relation to endometrial cancer; however, 
results have been inconclusive with limited evaluations of associations by subtype.11, 12 
Examination of associations with hypertensive disorders during pregnancy may provide 
insights into unrecognized biological mechanisms of endometrial carcinogenesis.13  
Large longitudinal datasets with decades of observations are needed to evaluate 
endometrial cancer associations with rare pregnancy conditions and/or to explore 
associations of timing of pregnancy across endometrial cancer subtypes. We therefore 














conducted a pooled analysis of population-based register data from four of the Nordic 
countries. We aimed to evaluate the risk of endometrial cancer, overall and by subtype, 
in relation to pregnancy-related factors, including pregnancy complications, and birth 
characteristics. 
Material and methods 
Data sources 
The nationwide health registers from Denmark, Finland, Norway, and Sweden, have 
been described previously.14-16 In brief, this study combined data across birth and 
cancer registers in each country. The population-based birth registers contain 
information on all births, including characteristics of both the mother and the offspring, in 
Norway since 1967, in Denmark and Sweden since 1973, and in Finland since 1987. 
Additional information on preeclampsia was identified from the Danish National Patient 
Registry 17, from the hospital and birth register in Finland, and from the birth register in 
Norway and Sweden.  
Reporting of cancer cases is compulsory in the Nordic countries, and their cancer 
registries cover the entire population starting in 1943 in Denmark, 1952 in Finland, 1953 
in Norway, and 1958 in Sweden. The unique identifiers used in all administrative and 
medical registers in the Nordic countries ensure accurate record linkage. Completeness 
and validity of the registers are high.18-21 
Study design/study population 














Using a nested case-control design the study included all first primary invasive uterine 
cancer cases and up to 10 controls per case (matched on country and birth year) 
among women registered with a prior pregnancy lasting at least 22 weeks in the birth 
registers. We sampled 10 controls per case to ensure we could stably represent the 
prevalence of the rare conditions in the underlying population. The study period was 
1973-2011 in Denmark, 1987-2012 in Finland, 1967-2013 in Norway, and 1974-2013 in 
Sweden. Uterine cancer cases (n=12,413) were identified using International 
Classification of Disease (ICD) topography codes (C54.0-55.9 from ICD-10 for 
reference) as follows: Denmark and Finland (ICD-10), Norway (ICD-O-3), and Sweden 
(ICD-7). The controls were sampled among the women in the birth registers with a prior 
pregnancy, who were alive and free of cancer at the time of diagnosis of the 
corresponding case.  
We first evaluated associations for endometrial cancers, limited to Type I and Type II 
cancers (n=10,924), thus excluding uterine carcinosarcoma (n=234), uterine sarcoma 
(n=737), and cases with missing histology (n=518). Next, we evaluated associations by 
histologic subtype based on morphology codes: endometrioid tumors (n=4994), 
adenocarcinoma (n=5271), serous (n=428), and clear cell (n=153) [we did not provide 
subtype analyses on mucinous (n=78) tumors given sparse data]; and by the dualistic 
classification of Type I (n=10,343, including endometrioid tumors, adenocarcinomas, 
and mucinous cancers) and Type II (n=581, including serous and clear cell) tumors for 
rare exposures (e.g., pre-existing conditions, pregnancy complications). 
The analytic dataset included information from the medical birth registers on all births 
until the date of diagnosis for cases and corresponding index date for controls. We 














obtained information on selected conditions (diabetes, chronic hypertension, rheumatoid 
arthritis, epilepsy, asthma) diagnosed before pregnancy, as well as maternal 
complications that occurred during any pregnancy (e.g., gestational diabetes, 
gestational hypertension, preeclampsia, etc). 
Data were complete for parity, age at last birth, and time since last birth; 46.2% of cases 
and 47.1% of controls lacked information on the first birth, primarily due to the relatively 
recent establishment of the birth registers. Data for pregnancy-related complications 
were available across all years of data collection and were characterized as being 
present (exposed) if they occurred in any pregnancy. Data on additional potential 
confounding factors, including maternal body mass index (BMI) and smoking (during 
pregnancy), were limited. BMI before or early in the last pregnancy was collected in 
Sweden starting in 1992, in Denmark and Finland starting in 2004, and in Norway 
starting in 2007. Information on smoking habits during pregnancy was first recorded in 
Sweden in 1982, Finland in 1987, Denmark in 1991, and Norway in 1999.  
The study was approved by ethics committees in Norway and Sweden and by the Data 
Protection Agency in Denmark. Permission to use health register data in Finland was 
granted by the National Institute of Health and Welfare after consultation with the data 
protection authority. The datasets analyzed as part of the current study are not freely 
available due to national regulations. 
Statistical analysis 
Associations, presented as odds ratios (ORs) with 95% confidence intervals (CIs), were 
estimated using unconditional logistic regression with adjustment for matching factors 














(country and categorical birth year [<1940, 1940-49, 1950-1959, 1960+]) and the 
following potential confounding factors (defined a priori): age at index date (continuous), 
marital status at first birth (unmarried, married/cohabiting, divorced/widowed, 
unknown/missing), pre- or early-pregnancy BMI at last pregnancy (<25, 25-29.9, ≥30 
kg/m2, unknown/missing). We report associations with and without adjustment for parity 
as relevant. Associations by dualistic Type or histologic subtype were estimated using 
multinomial logistic regression with the controls as the reference group and adjusting for 
matching factors and confounders as described. We utilized unconditional logistic 
regression for analyses of endometrial cancer risk overall, to ensure comparability with 
the multinomial models used to evaluate subtype associations. P values for 
heterogeneity across subgroup associations were estimated from models with the 
largest subgroup as the reference and excluded non-cases. 
In sensitivity analyses we evaluated associations restricted to women with available 
data on 1) BMI, 2) marital status, and 3) smoking in relation to any pregnancy with 
additional adjustment for smoking as a potential confounder. We evaluated 
simultaneous adjustment for chronic hypertension and diabetes prior to pregnancy 
(correlates (proxies) of increased BMI and risk factors for endometrial cancer in the 
current analysis) to further explore the possible effects of confounding by BMI. 
Adjustment for these variables individually or in combination did not change effect 
estimates substantially, and therefore we did not include them in our adjusted models. 
Data were analysed using SAS version 9.4 (Cary, North Carolina).  















Endometrial cancer cases were on average 57.8 years of age at diagnosis (standard 
deviation [SD]=8.0, Supplemental Table 1). The average time between a woman’s last 
birth and the index date was 26.7 years (SD=8.2) in cases and 25.5 years (SD=9.0) in 
controls. 
Maternal conditions and pregnancy-related complications 
Pre-existing diabetes and chronic hypertension were associated with increased 
endometrial cancer risk [OR (95% CI) diabetes=1.59 (1.22-2.07); hypertension OR=1.88 
(1.39-2.55)] (Table 1). Epilepsy during pregnancy was also associated with increased 
endometrial cancer risk [OR=1.46 (1.06-2.02)]. Other pre-existing conditions, like 
rheumatoid arthritis and asthma, were not associated with risk. 
Gestational diabetes was associated with a modestly elevated endometrial cancer risk, 
albeit it was not statistically significant [OR=1.27 (0.81-1.99)] (Table 1). Hypertension 
diagnosed during pregnancy was associated with increased endometrial cancer risk 
[OR=1.47 (1.33-1.63)], as was preeclampsia [OR=1.43 (1.30-1.58)]. Associations were 
consistent with and without adjustment for parity. Further, both pre-existing 
hypertension [OR=1.74 (1.28-2.35)] and gestational hypertension [OR=1.44 (1.30-1.59)] 
remained associated with increased risk of endometrial cancer in mutually adjusted 
models (results not tabulated).  
(Table 1 here) 














Chronic hypertension, gestational hypertension, and preeclampsia were associated with 
increased risks of both Type I and Type II endometrial tumors [chronic hypertension: 
Type I=1.88 (1.38-2.56), Type II=1.78 (0.44-7.21); gestational hypertension: Type 
I=1.45 (1.31-1.61), Type II=1.42 (0.92-2.18); preeclampsia: Type I=1.44 (1.30-1.59), 
Type II=1.39 (0.91-2.15); P values for heterogeneity>0.05] (Table 1).  
Other pregnancy-related characteristics, including hyperemesis gravidarum [OR=0.93 
(0.74-1.18)], abruptio placentae [OR=1.07 (0.88-1.29)], or antepartum haemorrhage 
[OR=1.08 (0.83-1.40)], were not associated with endometrial cancer risk. Women 
whose most recent infant was born in the highest categories of birthweight were at 
increased risk [4000-4499 vs. 2500-3999 grams: OR=1.22 (1.16-1.29); ≥4500 vs. 2500-
3999 grams: OR=1.39 (1.22-1.47)]. A higher placental weight in the last pregnancy was 
associated with increased endometrial cancer risk in the mother [≥700 vs. 500-699 
grams: OR=1.50 (1.26-1.78)], while lower placental weight was not associated with risk 
[<500 vs. 500-699 grams: OR=0.99 (0.78-1.26)]. 
Our data suggest that the birth weight association may be heterogenous by Type I/II 
subtype (P heterogeneity=0.09); the highest categories of birthweight were associated 
with increased risk of Type I tumors [4000-4499 vs. 2500-3999 grams: OR=1.21 (1.14-
1.27); ≥4500 vs. 2500-3999 grams: OR=1.36 (1.24-1.50)] and a null association for 
Type II tumors [ORs=1.08 (0.86-1.34); 0.97 (0.63-1.51), respectively]; while the lowest 
category of birthweight was associated with increased risk of Type II tumors [<1000 vs. 
2500-4000 grams: OR=3.52 (1.30-9.56)] but not with Type I tumors [OR=1.11 (0.72-
1.70)]. Associations with the other factors evaluated were not strongly heterogeneous 
across Type I and II tumors.   














Parity and timing of pregnancy 
Compared with having one recorded birth, increased parity progressively decreased risk 
of endometrial cancer [e.g., four or more births: OR=0.64 (0.59-0.69)] (Table 2). Older 
age at and shorter time since first birth were both associated with substantial reductions 
in endometrial cancer risk [≥40 vs.<20 years old: OR=0.44 (0.29-0.66); <10 vs. ≥30 
years since first birth: OR=0.51 (0.39-0.65)] as were older age at and shorter time since 
last birth [≥45 vs.<25 years old: OR=0.69 (0.53-0.89); <10 vs. ≥30 years since last birth: 
OR=0.31 (0.26-0.36)]. Simultaneous adjustment for age at and time since birth in the 
analytic models did not substantially change the interpretation of the results (data not 
shown).  
(Table 2 here) 
The risk reductions for age at first and age at last birth were similar among women who 
had only one birth (uniparous) and those who had more than one birth (Supplemental 
Table 2). However, the risk reductions for time since first and last birth among 
multiparous women were greater than among the uniparous women [e.g., time since 
first birth <10 vs. ≥30 years: uniparous OR=0.43 (0.30-0.61); multiparous OR=0.24 
(0.15-0.38)]. 
Increasing number of births was associated with equivalent reductions in risk for Type I 
and Type II endometrial cancers (Table 2). When evaluating individual subtypes (Table 
3), reductions in risk for four or more births compared with one birth were apparent for 
endometrioid tumors [OR=0.63 (0.56-0.71)], and adenocarcinomas [OR=0.64 (0.57-














0.72)]. Similar reductions were also suggested for serous [OR=0.72 (0.48-1.10)] and 
clear cell tumors [OR=0.60 (0.30-1.23); P heterogeneity=0.03]. 
(Table 3 here) 
Older age at first birth and shorter time since first birth were associated with strong risk 
reductions for Type I tumors, with very weak reductions in risk or no association 
suggested for Type II tumors [e.g., time since first birth <10 vs. ≥30 years: Type I 
OR=0.40 (0.31-0.52); Type II OR=0.75 (0.20-2.82); P heterogeneity=0.01]. This pattern 
was consistent when evaluating individual subtypes. For example, shorter time since 
first birth was associated with reductions in risk for endometrioid [OR=0.33 (0.22-0.50)] 
and adenocarcinomas [OR=0.41 (0.29-0.58)], but not for the other subtypes (P 
heterogeneity<0.001). 
Older age at last birth and shorter time since last birth were associated with strong risk 
reductions for both Type I and Type II endometrial cancers [e.g., time since last birth 
<10 vs. ≥30 years: Type I OR=0.36 (0.31-0.43); Type II OR=0.22 (0.08-0.59); P 
heterogeneity<0.01]. Risk reductions within these same categories of time since last 
birth were observed for endometrioid tumors [OR=0.31 (0.25-0.40)], adenocarcinoma 
[OR=0.39 (0.31-0.48)], serous [OR=0.19 (0.05-0.75)], and clear cell [OR=0.25 (0.06-
1.15); P heterogeneity<0.001] endometrial cancers.  
In sensitivity analyses effect estimates conveyed a similar pattern of risk after: 1) 
excluding individuals with missing data on BMI (Supplemental Table 3), 2) excluding 
individuals with missing data on marital status (results not shown), or 3) adjusting for 
smoking status (results not shown), and 4) excluding individuals with missing smoking 














status in models adjusting for smoking status (results not shown). Given that BMI is a 
very strong, if not the strongest, endometrial cancer risk factor, we were concerned 
about the potential bias that could have been introduced by not adjusting for BMI in our 
analysis or using a missing indicator. Although imprecise, the effect estimates limiting 
the study population to cases and controls with available pre-pregnancy BMI data and 
adjusted for BMI (complete case analyses) were remarkably consistent with the full 
study population analysis adjusted for BMI with a missing indicator. For example, risk 
estimates for exposures most plausibly confounded by BMI were as follows [full study 
population vs. complete case analysis]: diabetes, 1.59 (1.23-2.07) vs. 1.60 (0.88-2.93); 
chronic hypertension 1.83 (1.35-2.48) vs. 1.78 (0.93-3.42); gestational hypertension 
1.45 (1.32-1.60) vs. 1.49 (0.63-3.52); and preeclampsia 1.41 (1.28-1.56) vs. 1.66 (1.25-
2.19) (Supplemental Table 3).    
Discussion 
In this large analysis of linked registry data in four Nordic countries, hypertensive 
conditions, whether diagnosed before or during pregnancy, including preeclampsia, 
were associated with increased risk of endometrial cancer, with consistent associations 
by dualistic tumor Types (Type I and II). The association between birthweight and 
endometrial cancer risk appeared heterogenous by subtype, with elevated risks with 
high birthweights (4000+ grams) for Type I tumors, and with very low birthweights 
(<1000 grams) for Type II tumors. With respect to number and timing of pregnancies, 
we observed reductions in endometrial cancer risk across most of the subtypes with 
increasing number of pregnancies and shorter time since last birth.  














Prior studies evaluating preeclampsia and endometrial cancer risk are rare and limited 
by small numbers given the relatively low prevalence of preeclampsia.11, 12 A study 
utilizing linked register data in Denmark reported an increased endometrial cancer risk 
with early onset preeclampsia (22-33 weeks of gestation, 9 exposed cases) and no 
association with late onset disease (>33 weeks of gestation, 5 exposed cases),12 while 
the Jerusalem Perinatal Study (n=9 exposed cases) showed no association between 
preeclampsia and uterine cancer.11 Data on gestational age were not collected in the 
Jerusalem Perinatal Study, but it is likely that many of the preeclampsia diagnoses are 
late onset. Further, edema was included in the early definition for preeclampsia utilized 
in the Jerusalem study and it is not included in contemporary definitions utilized in the 
Danish study and our current study,22 thus results may not be directly comparable.  
Preeclampsia is characterized by elevated blood pressure and urinary protein excretion, 
and it is suggested that the protective effects of preeclampsia on breast cancer risk are 
via altered circulating hormone levels associated with the syndrome. Increased 
androgen levels in preeclampsia may well be a possible factor since increased serum 
androgens are associated with increased risk of endometrial cancer in postmenopausal 
women (reviewed in 23). This is consistent with an increased risk of endometrial cancer 
in women with polycystic ovary syndrome (reviewed in 24). In addition, increased risks 
associated with hypertension, as well as preeclampsia, suggest that immunologic 
and/or inflammatory etiologies during and preceding pregnancy may also be relevant 
factors in endometrial carcinogenesis. Specifically, preeclampsia has been associated 
with inflammation and immune activation in both maternal circulation and the 
uteroplacental unit25, which may be relevant to increased endometrial cancer risk. 














Epidemiologic data that support a possible role of inflammation in the development of 
endometrial cancer are emerging. Inflammation-related exposures such as obese BMI 
and diabetes, as well as circulating biomarkers of inflammation have been associated 
with endometrial cancer risk.10, 26 Further, aspirin and non-aspirin nonsteroidal anti-
inflammatory drug use are associated with modest reductions in endometrial cancer risk 
in some studies.27 
Pregnancy affects many endogenous systems. Thus the mechanisms by which all 
births, but specifically births later in life, may reduce endometrial cancer risk in the 
mother include: 1) exposures to higher levels of progesterone (relative to estrogen) 
throughout pregnancy which possibly facilitate removal/apoptosis of premalignant 
lesions (e.g., reduction in endometrial hyperplasia with progesterone treatment in the 
PEPI trial 28; 2) mechanical removal/sloughing of premalignant cells during parturition 
and/or uterine involution; 3) immune-mediation during pregnancy. Other hormones 
produced in the placenta may also be related to the carcinogenic process13, but have 
not been evaluated with respect to endometrial cancer. Finally, it is also possible that 
women capable of maintaining a pregnancy at a late age may simply have a healthy 
uterus or have experienced fewer anovulatory cycles.  
Our results are consistent with prior studies evaluating overall endometrial cancer risk 
and number of pregnancies and timing of pregnancy.3-7, 9, 10 Our study is also consistent 
with prior research suggesting that parity is associated with similar reductions in risk by 
dualistic Type and histologic subtype.9, 10 Our results differ from these prior studies in 
that we report that older age at first birth and shorter time since first birth were 
associated with strong risk reductions for Type I tumors compared with Type II tumors, 














while shorter time since last birth was associated with stronger risk reductions for Type 
II tumors.  
Among the strengths of our study are the very large study size, inclusion of 
histologically verified cancer cases among women with at least one registered 
pregnancy in four Nordic countries, and linkages among comprehensive and 
mandatorily established databases with reliable information. The study design using 
standardized data from registers also minimizes bias due to participant self-selection or 
recall of information. Residual confounding by BMI is possible. However, we compared 
our full analysis adjusted for BMI with a complete case analysis—limiting the study 
population to cases and controls with complete BMI data and adjusting for BMI—and 
the effect estimates, and thus interpretation of the associations, across these two 
analyses were remarkably consistent. Additional limitations include the lack of details on 
possible confounders, such as use of exogenous hormones. Menopausal hormone 
therapy is unlikely to be a confounder as it does not precede exposure and is not 
associated with the exposures evaluated. The use of oral contraceptives, a known 
protective factor for endometrial cancer, may be correlated with maternal characteristics 
like age at first/last pregnancy. However, we could not adjust for this factor in our 
analysis due to lack of information in the birth/cancer registers. As information on 
hysterectomy status was not available across all registers, we did not limit control 
selection to women with no history of hysterectomy. However, the prevalence of 
hysterectomy in the Nordic countries is low, reducing the potential impact of this bias.29-
32  














In conclusion, our data support an important role for hormonal exposures during 
pregnancy and/or cell clearance in the etiology of endometrial cancer. Our data also 
suggest that pregnancy-related immunologic and/or inflammatory exposures may be 
relevant to endometrial carcinogenesis, given the increased risks we observed for 
gestational hypertension and preeclampsia. Future research should consider 
evaluations of endometrial hyperplasia, an endometrial cancer precursor condition, in 
the context of pregnancy related exposures. This may help provide insight into the 
mechanisms by which pregnancy protects against subsequent endometrial cancer risk, 
although some pregnancy related exposures (i.e., hypertension and preeclampsia) 
increase risk.    
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Table 1. Maternal conditions and pregnancy-related complications and subsequent endometrial cancer risk, overall and by dualistic subtype; Nordic countries, 1967-2013. 
 
Controls                
(N=123 749) Endometrial Cancer Cases (N=10 924)  Type I (N=10 343)   Type II (N=581)  
 
 
n (%) n (%) OR
a
 (95% CI) OR
b
 (95% CI) n (%) OR
b
 (95% CI) n (%) OR
b
 (95% CI) P 
Pre-existing conditions (recorded at any pregnancy) 
            Diabetes 444 (0.4) 65 (0.6) 1.59 (1.23-2.07) 1.59 (1.22-2.07) 65 (0.6) 1.66 (1.27-2.15) 0 (0.0) -- -- -- 
   Chronic 
Hypertension 299 (0.2) 49 (0.5) 1.83 (1.35-2.48) 1.88 (1.39-2.55) 47 (0.5) 1.88 (1.38-2.56) 2 (0.3) 1.78 (0.44-7.21) 0.96 
   Rheumatoid 
Arthritis
c
 157 (0.2) 12 (0.2) 0.90 (0.50-1.62) 0.91 (0.50-1.63) 12 (0.2) 0.95 (0.53-1.71) 0 (0.0) -- -- -- 
   Epilepsy
c
 334 (0.3) 42 (0.4) 1.46 (1.06-2.01) 1.46 (1.06-2.02) 41 (0.4) 1.50 (1.08-2.08) 1 (0.2) -- -- -- 
   Asthma 941 (0.8) 80 (0.7) 0.99 (0.78-1.24) 1.01 (0.80-1.27) 76 (0.7) 1.00 (0.79-1.27) 4 (0.7) 1.18 (0.44-3.18) 0.51 
Gestational Complications (diagnosed in any pregnancy) 
            Gestational 
diabetes
c
 216 (0.4) 21 (0.4) 1.23 (0.78-1.93) 1.27 (0.81-1.99) 20 (0.4) 1.20 (0.76-1.91) 1 (0.4) -- -- -- 
   Gestational 
hypertension
c
 3961 (6.5) 476 (9.2) 1.45 (1.32-1.60) 1.47 (1.33-1.63) 453 (9.3) 1.45 (1.31-1.61) 23 (8.2) 1.42 (0.92-2.18) 0.77 
   Preeclampsia 3795 (3.1) 470 (4.3) 1.41 (1.28-1.56) 1.43 (1.30-1.58) 448 (4.3) 1.44 (1.30-1.59) 22 (3.8) 1.39 (0.91-2.15) 0.82 
   Hyperemesis 
gravidarum 978 (0.8) 78 (0.7) 0.91 (0.72-1.15) 0.93 (0.74-1.18) 76 (0.7) 0.97 (0.76-1.22) 2 (0.3) 0.45 (0.11-1.80) 0.30 
   Abruptio placentae 1231 (1.0) 113 (1.0) 1.02 (0.84-1.24) 1.07 (0.88-1.29) 109 (1.1) 1.08 (0.89-1.32) 4 (0.7) 0.76 (0.28-2.04) 0.66 
   Antepartum 
hemorrhage
c
 642 (0.9) 62 (1.0) 1.04 (0.80-1.36) 1.08 (0.83-1.40) 60 (0.6) 1.06 (0.81-1.39) 2 (0.3) 0.71 (0.18-2.85) 0.69 
Birth characteristics (most recent birth) 
           Birth weight, grams 
                <1000 258 (0.2) 27 (0.3) 1.23 (0.83-1.83) 1.23 (0.82-1.83) 23 (0.2) 1.11 (0.72-1.70) 4 (0.7) 3.52 (1.30-9.56) 0.12 
   1000-1499 506 (0.4) 52 (0.5) 1.21 (0.91-1.61) 1.20 (0.90-1.60) 49 (0.5) 1.20 (0.89-1.61) 3 (0.5) 1.25 (0.40-3.91) 
    1500-2499 4384 (3.6) 353 (3.2) 0.95 (0.85-1.07) 0.94 (0.84-1.05) 336 (3.3) 0.95 (0.85-1.06) 17 (2.9) 0.84 (0.52-1.37) 
    2500-3999 94613 (76.7) 8003 (73.5) 1.00 reference 1.00 reference 9902 (96.0) 1.00 reference 554 (95.9) 1.00 reference 
    4000-4499 19034 (15.4) 1927 (17.7) 1.20 (1.14-1.26) 1.22 (1.16-1.29) 1832 (17.8) 1.21 (1.14-1.27) 95 (16.4) 1.08 (0.86-1.34) 
     ≥4500 4630 (3.8) 526 (4.8) 1.34 (1.22-1.47) 1.39 (1.27-1.53) 505 (4.9) 1.36 (1.24-1.50) 21 (3.6) 0.97 (0.63-1.51)  
Low birth weight in 
last birth (<2500 
grams) 5148 (4.2) 432 (4.0) 0.95 (0.86-1.05) 0.94 (0.85-1.04) 408 (4.0) 0.93 (0.84-1.04) 24 (4.2) 1.00 (0.66-1.51) 0.59 
Preterm delivery 6891 (5.6) 675 (6.2) 1.11 (1.03-1.21) 1.11 (1.02-1.20) 646 (6.3) 1.12 (1.03-1.22) 29 (5.1) 0.88 (0.60-1.28) 0.22 
Placental weight, 
grams 
             
















   <500 1296 (14.1) 90 (13.0) 1.02 (0.80-1.29) 0.99 (0.78-1.26) 84 (12.6) 0.95 (0.74-1.22) 6 (20.7) 1.93 (0.72-5.20) 0.66 
   500-699 5149 (56.0) 348 (50.1) 1.00 reference 1.00 reference 336 (50.5) 1.00 reference 12 (41.4) 1.00 reference 
    ≥700 2758 (30.0) 256 (36.9) 1.47 (1.24-1.75) 1.50 (1.26-1.78) 245 (36.8) 1.49 (1.25-1.78) 11 (37.9) 1.77 (0.77-4.08)   
a
 Unconditional logistic regression models adjusted for matching factors (country, birth year), index age, body mass index, and marital status at first pregnancy. 
 
b 
Unconditional logistic regression models adjusted for matching factors (country, birth year), index age, body mass index, marital status at first pregnancy, and parity. 
Index age was defined as the age at endometrial cancer diagnosis among cases and age at endometrial cancer of the matched case among controls. 
P for heterogeneity 
C
 Due to complete/near complete (>99%) missing data models exclude the following: data from Sweden for Rheumatoid Arthritis, data from Finland for Epilepsy, data from Norway for 
Antepartum hemorrhage, data from Sweden before 1997 and data from Denmark before 1995 for gestational diabetes and gestational hypertension.  















Table 2. Number and timing of births and endometrial cancer risk; Nordic countries, 1967-2013.  
 
Controls                
(N=123 749) 
Endometrial cancer cases 
(N=10 924)              Type I (N=10 343) Type II (N=581) 
 Parity n (%) n (%) OR
a
 (95% CI) OR
b
 (95% CI) n (%) OR
a
 (95% CI) n (%) OR
a
 (95% CI) P 
   1 birth 14669 (11.9) 1607 (14.7) 1.00 reference 
  
1545 (14.9) 1.00 reference 62 (10.7) 1.00 reference 
    2 births 49314 (39.9) 4596 (42.1) 0.83 (0.78-0.88) 
  
4350 (42.1) 0.81 (0.76-0.87) 246 (42.3) 1.08 (0.80-1.45) 0.19 
   3 births 35948 (29.1) 2946 (27.0) 0.71 (0.67-0.77) 
  
2774 (26.8) 0.70 (0.66-0.76) 172 (29.6) 0.91 (0.66-1.25) 
    4+ births 23818 (19.3) 1775 (16.3) 0.64 (0.59-0.69) 
  
1674 (16.2) 0.63 (0.58-0.69) 101 (17.4) 0.69 (0.48-0.99) 
 Age first birth 
      
     
    <20 11454 (9.3) 1238 (11.3) 1.00 reference 1.00 reference 1179 (11.4) 1.00 reference 59 (10.2) 1.00 reference 
    20-24 35783 (28.9) 3500 (32.0) 0.88 (0.82-0.94) 0.92 (0.86-0.99) 3335 (32.2) 0.93 (0.87-1.00) 165 (28.4) 0.77 (0.56-1.04) 0.01 
   25-29 43126 (34.9) 3704 (33.9) 0.74 (0.69-0.80) 0.80 (0.75-0.86) 3515 (34.0) 0.82 (0.76-0.88) 189 (32.5) 0.68 (0.49-0.93) 
    30-34 25723 (20.8) 1929 (17.7) 0.62 (0.57-0.67) 0.67 (0.62-0.73) 1814 (17.5) 0.68 (0.62-0.74) 115 (19.8) 0.64 (0.45-0.92) 
    35-39 7232 (5.8) 528 (4.8) 0.58 (0.51-0.65) 0.63 (0.56-0.71) 480 (4.6) 0.62 (0.55-0.70) 48 (8.3) 0.85 (0.55-1.33) 
    ≥40 431 (0.4) 25 (0.2) 0.44 (0.29-0.66) 0.48 (0.32-0.72) 20 (0.2) 0.42 (0.27-0.67) 5 (0.9) 1.34 (0.52-3.47) 
 Time since first birth, years 
               <10 1958 (3.0) 90 (1.5) 0.51 (0.39-0.65) 0.37 (0.29-0.48) 86 (1.5) 0.40 (0.31-0.52) 4 (1.6) 0.75 (0.20-2.82) 0.01 
   10-19 9375 (14.3) 708 (12.1) 0.82 (0.72-0.92) 0.69 (0.61-0.78) 689 (12.3) 0.73 (0.64-0.82) 19 (7.7) 0.72 (0.37-1.39) 
    20-29 23395 (35.8) 2190 (37.4) 1.01 (0.94-1.09) 0.93 (0.87-1.00) 2143 (38.2) 0.96 (0.90-1.03) 47 (19.1) 0.56 (0.39-0.83) 
    ≥30 30702 (46.9) 2866 (49.0) 1.00 reference 1.00 reference 2690 (48.0) 1.00 reference 176 (71.5) 1.00 reference 
 Age last birth 
               <25 4940 (7.6) 485 (8.3) 1.00 reference 1.00 reference 460 (8.2) 1.00 reference 25 (10.2) 1.00 reference 
    25-29 22577 (34.5) 2140 (36.6) 0.94 (0.85-1.05) 0.92 (0.83-1.02) 2065 (36.8) 0.94 (0.85-1.05) 75 (30.5) 0.52 (0.33-0.84) 0.12 
   30-34 22423 (34.3) 1894 (32.4) 0.82 (0.73-0.91) 0.76 (0.68-0.85) 1810 (32.3) 0.78 (0.70-0.88) 84 (34.2) 0.49 (0.30-0.80) 
    35-39 10359 (15.8) 890 (15.2) 0.80 (0.71-0.91) 0.69 (0.61-0.79) 847 (15.1) 0.71 (0.62-0.81) 43 (17.5) 0.46 (0.26-0.81) 
    40-44 4133 (6.3) 364 (6.2) 0.78 (0.67-0.92) 0.62 (0.52-0.72) 351 (6.3) 0.64 (0.55-0.76) 13 (5.3) 0.29 (0.13-0.62) 
    ≥45 998 (1.5) 81 (1.4) 0.69 (0.53-0.89) 0.50 (0.39-0.65) 75 (1.3) 0.51 (0.39-0.67) 6 (2.4) 0.47 (0.17-1.31) 
 Time since last birth, years 
               <10 6998 (5.7) 281 (2.6) 0.31 (0.26-0.36) 0.34 (0.29-0.40) 274 (2.7) 0.36 (0.31-0.43) 7 (1.2) 0.22 (0.08-0.59) 0.001 
   10-19 26380 (21.3) 2037 (18.7) 0.67 (0.62-0.73) 0.73 (0.67-0.79) 1995 (19.3) 0.78 (0.72-0.84) 42 (7.2) 0.38 (0.24-0.59) 
    20-29 48467 (39.2) 4596 (42.1) 0.91 (0.86-0.96) 0.95 (0.90-1.01) 4425 (42.8) 0.99 (0.93-1.05) 171 (29.4) 0.66 (0.53-0.83) 
    ≥30 41904 (33.9) 4010 (36.7) 1.00 reference 1.00 reference 3649 (35.3) 1.00 reference 361 (62.1) 1.00 reference 
 a Unconditional logistic regression models adjusted for matching factors (country, birth year), index age, body mass index, and marital status at first pregnancy. 
b
 Unconditional logistic regression models adjusted for matching factors (country, birth year), index age, body mass index, marital status at first pregnancy, and parity.  
Index age was defined as the age at endometrial cancer diagnosis among cases and age at endometrial cancer of the matched case among controls. 
P heterogeneity 














Table 3. Number and timing of births and endometrial cancer risk by histologic subtype; Nordic countries, 1967-2013. 
 
Endometrioid (n=4994) Adenocarcinoma (n=5271) Mucinous
b
 (n=78) 
Parity n (%) OR
a
 (95% CI) n (%) OR
a
 (95% CI) n (%)   
   1 birth 689 (13.8) 1.00 reference 850 (16.1) 1.00 reference 6 (7.7)   
   2 births 2031 (40.7) 0.84 (0.76-0.92) 2279 (43.2) 0.78 (0.72-0.85) 40 (51.3)   
   3 births 1391 (27.9) 0.74 (0.67-0.82) 1363 (25.9) 0.66 (0.60-0.73) 20 (25.6)   
   4+ births 883 (17.7) 0.63 (0.56-0.71) 779 (14.8) 0.64 (0.57-0.72) 12 (15.4)   
Age first birth 
       
  
   <20 679 (13.6) 1.00 reference 496 (9.4) 1.00 reference 4 (5.1)   
   20-24 1691 (33.9) 0.95 (0.86-1.04) 1617 (30.7) 0.90 (0.81-1.00) 27 (34.6)   
   25-29 1621 (32.5) 0.85 (0.77-0.94) 1864 (35.4) 0.77 (0.69-0.87) 30 (38.5)   
   30-34 784 (15.7) 0.69 (0.62-0.78) 1016 (19.3) 0.62 (0.55-0.71) 14 (18.0)   
   35-39 213 (4.3) 0.65 (0.55-0.77) 264 (5.0) 0.56 (0.47-0.66) 3 (3.9)   
   ≥40 6 (0.1) 0.28 (0.13-0.64) 14 (0.3) 0.48 (0.28-0.84) 0 (0.0)   
Time since first birth, years 
     
   
   <10 33 (1.1) 0.33 (0.22-0.50) 53 (2.0) 0.41 (0.29-0.58) 0 (0.0)   
   10-19 286 (9.9) 0.63 (0.52-0.75) 400 (15.0) 0.74 (0.63-0.87) 3 (7.7)   
   20-29 969 (33.4) 0.93 (0.84-1.02) 1154 (43.3) 0.98 (0.88-1.09) 20 (51.3)   
   ≥30 1614 (55.6) 1.00 reference 1060 (39.8) 1.00 reference 16 (41.0)   
Age last birth 
       
  
   <25 319 (11.0) 1.00 reference 138 (5.2) 1.00 reference 3 (7.7)   
   25-29 1215 (41.9) 0.91 (0.79-1.03) 839 (31.5) 1.09 (0.90-1.31) 11 (28.2)   
   30-34 861 (29.7) 0.75 (0.65-0.86) 929 (34.8) 0.88 (0.72-1.07) 20 (51.3)   
   35-39 339 (11.7) 0.71 (0.59-0.84) 503 (18.9) 0.78 (0.63-0.96) 5 (12.8)   
   40-44 135 (4.7) 0.67 (0.53-0.84) 216 (8.1) 0.64 (0.49-0.82) 0 (0.0)   
   ≥45 33 (1.1) 0.60 (0.41-0.89) 42 (1.6) 0.44 (0.30-0.65) 0 (0.0)   
Time since last birth, years 
     
   
   <10 118 (2.4) 0.31 (0.25-0.40) 155 (2.9) 0.39 (0.31-0.48) 1 (1.3)   
   10-19 814 (16.3) 0.62 (0.55-0.70) 1170 (22.2) 0.87 (0.78-0.98) 11 (14.1)   
   20-29 1995 (40.0) 0.92 (0.85-1.00) 2387 (45.3) 1.04 (0.96-1.13) 43 (55.1)   
   ≥30 2067 (41.4) 1.00 reference 1559 (29.6) 1.00 reference 23 (29.5)   
      



























Table 3. Cont'd 
Serous (n=428) Clear Cell (n=153) 
Parity n (%) OR
a
 (95% CI) n (%) OR
a
 (95% CI)  P heterogeneity 
     1 birth 46 (10.8) 1.00 reference 16 (10.5) 1.00 reference 0.03 
     2 births 178 (41.6) 1.07 (0.76-1.51) 68 (44.4) 1.12 (0.63-1.99) 
      3 births 126 (29.4) 0.91 (0.62-1.33) 46 (30.1) 0.90 (0.48-1.69) 
      4+ births 78 (18.2) 0.72 (0.48-1.10) 23 (15.0) 0.60 (0.30-1.23) 
   Age first birth 
            <20 41 (9.6) 1.00 reference 18 (11.8) 1.00 reference 0.005 
     20-24 118 (27.6) 0.78 (0.54-1.13) 47 (30.7) 0.73 (0.41-1.28) 
      25-29 143 (33.4) 0.74 (0.50-1.08) 46 (30.1) 0.54 (0.30-0.98) 
      30-34 86 (20.1) 0.70 (0.45-1.07) 29 (19.0) 0.51 (0.26-1.01) 
      35-39 36 (8.4) 0.94 (0.56-1.57) 12 (7.8) 0.66 (0.28-1.54) 
      ≥40 4 (0.9) 1.55 (0.53-4.54) 1 (0.7) 0.83 (0.10-6.64) 
   Time since first birth, years 
      
<0.001 
     <10 2 (1.1) 0.79 (0.14-4.51) 2 (3.0) 0.74 (0.10-5.66) 
      10-19 11 (6.1) 0.62 (0.27-1.44) 8 (12.1) 0.87 (0.29-2.61) 
      20-29 28 (15.6) 0.48 (0.30-0.77) 19 (28.8) 0.78 (0.40-1.52) 
      ≥30 139 (77.2) 1.00 reference 37 (56.1) 1.00 reference 
   Age last birth 
            <25 19 (10.6) 1.00 reference 6 (9.1) 1.00 reference <0.001 
     25-29 55 (30.6) 0.49 (0.28-0.84) 20 (30.3) 0.62 (0.24-1.58) 
      30-34 61 (33.9) 0.45 (0.25-0.80) 23 (34.9) 0.59 (0.22-1.56) 
      35-39 32 (17.8) 0.44 (0.23-0.84) 11 (16.7) 0.51 (0.17-1.56) 
      40-44 10 (5.6) 0.28 (0.11-0.69) 3 (4.6) 0.29 (0.06-1.41) 
      ≥45 3 (1.7) 0.29 (0.08-1.13) 3 (4.6) 1.10 (0.21-5.84) 
   Time since last birth, years 
      
<0.001 
     <10 3 (0.7) 0.19 (0.05-0.75) 4 (2.6) 0.25 (0.06-1.15) 
      10-19 28 (6.5) 0.38 (0.23-0.65) 14 (9.2) 0.36 (0.16-0.80) 
      20-29 116 (27.1) 0.62 (0.48-0.81) 55 (36.0) 0.76 (0.49-1.19) 
      ≥30 281 (65.7) 1.00 reference 80 (52.3) 1.00 reference 
   
a
 Multinomial logistic regression model adjusted for matching factors (country, birth year), index age, body mass index, and marital status at first pregnancy. 
Index age was defined as the age at endometrial cancer diagnosis among cases and age at endometrial cancer of the matched case among controls. 
b
 Given sparse data for mucinous tumors we provide case counts and percent for comparison but do not report effect estimates. 
 
  














Novelty and Impact: 
Many pregnancy-related factors are associated with reduced endometrial-cancer risk. Are pregnancy-related complications also 
associated with altered risk? In study, the authors found that pre-existing and gestational hypertension, as well as preeclampsia, were 
associated with an increased risk of endometrial cancer, suggesting that immunologic and/or inflammatory etiologies may be relevant 
in endometrial carcinogenesis. They also conclude that the reduced risk associated with higher parity and later age also suggest an 
important role for hormonal and cell-clearance mechanisms. These results support further study of how endometrial hyperplasia in the 
context of pregnancy-related exposures influences cancer risk. 
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